- Home
- EDU vs ROIV Comparison
EDU vs ROIV Comparison
Compare EDU & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDU
- ROIV
- Stock Information
- Founded
- EDU 1993
- ROIV 2014
- Country
- EDU China
- ROIV United Kingdom
- Employees
- EDU N/A
- ROIV N/A
- Industry
- EDU Other Consumer Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- EDU Real Estate
- ROIV Health Care
- Exchange
- EDU Nasdaq
- ROIV Nasdaq
- Market Cap
- EDU 8.5B
- ROIV 14.0B
- IPO Year
- EDU 2006
- ROIV N/A
- Fundamental
- Price
- EDU $51.68
- ROIV $20.23
- Analyst Decision
- EDU Buy
- ROIV Strong Buy
- Analyst Count
- EDU 6
- ROIV 8
- Target Price
- EDU $57.87
- ROIV $21.19
- AVG Volume (30 Days)
- EDU 1.2M
- ROIV 8.7M
- Earning Date
- EDU 10-28-2025
- ROIV 11-10-2025
- Dividend Yield
- EDU 2.32%
- ROIV N/A
- EPS Growth
- EDU N/A
- ROIV N/A
- EPS
- EDU 2.27
- ROIV N/A
- Revenue
- EDU $4,987,826,000.00
- ROIV $20,329,000.00
- Revenue This Year
- EDU $10.42
- ROIV N/A
- Revenue Next Year
- EDU $10.31
- ROIV $320.50
- P/E Ratio
- EDU $22.80
- ROIV N/A
- Revenue Growth
- EDU 7.29
- ROIV N/A
- 52 Week Low
- EDU $40.66
- ROIV $8.73
- 52 Week High
- EDU $68.53
- ROIV $21.35
- Technical
- Relative Strength Index (RSI)
- EDU 37.30
- ROIV 61.82
- Support Level
- EDU $51.50
- ROIV $20.07
- Resistance Level
- EDU $53.68
- ROIV $20.99
- Average True Range (ATR)
- EDU 1.27
- ROIV 0.77
- MACD
- EDU -0.68
- ROIV -0.21
- Stochastic Oscillator
- EDU 17.76
- ROIV 44.31
About EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.